Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Site for A Phase III Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK7339-013)

This is a Phase 3 Study of the study drug Pembro in combination with chemoradiation followed by Pembro alone or with a combination of Pembro/Olaparib in subjects without prior treatment of Limited Stage Small Cell Lung Cancer.
Irina Geier at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04380636
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Has pathologically (histologically or cytologically) confirmed SCLC.
Has LS-SCLC (Stage I-III, by AJCC 8th Edition Cancer Staging), and can be safely treated with definitive radiation doses.
Has no evidence of metastatic disease by whole body PET/CT scan, CT or MRI scans of diagnostic quality of chest, abdomen, pelvis and brain.
Has not received prior treatment (chemotherapy or radiotherapy or surgery resection) of LS-SCLC.
Has ECOG Performance score 0 or 1 assessed within 7 days prior to the first administration of study intervention.
Exclusion Criteria:
Has history, current diagnosis, or features suggestive of MDS/AML.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
Has received prior therapy with olaparib or with any other PARP inhibitor.
Had major surgery <4 weeks prior to the first dose of study intervention
Has received colony-stimulating factors 28 days prior to the first dose of study intervention.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA